08:36 AM EDT, 05/28/2024 (MT Newswires) -- FSD Pharma ( HUGE ) on Tuesday said it has submitted a clinical trial protocol to the Institutional Review Board (IRB) in the U.S. to assess the safety and efficacy of Unbuzzd in healthy volunteers in the METAL-2 trial. Recruitment of healthy volunteers will begin following approval. In the METAL-2 trial, the ability of Unbuzzd to help alleviate the effects of acute alcohol intoxication will be studied in a crossover design, the company said,

"We are thrilled that we have reached this important milestone and that we are now a step closer to assessing the safety and efficacy of Unbuzzd in a clinical trial," said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at FSD Pharma ( HUGE ).